• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FOXM1和PLK1的表达可预测肝细胞癌患者的预后。

Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.

作者信息

Fan Weiqiang, Ma Huan, Jin Bin

机构信息

Department of Organ Transplantation, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.

出版信息

Oncol Lett. 2022 May;23(5):146. doi: 10.3892/ol.2022.13266. Epub 2022 Mar 15.

DOI:10.3892/ol.2022.13266
PMID:35350587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8941521/
Abstract

Hepatocellular carcinoma (HCC) is one of the most frequently encountered malignant tumor types and to improve its treatment, effective prognostic biomarkers are urgently required. Cell cycle dysregulation is a significant feature of cancer progression. The aim of the present study was to estimate the expression levels of forkhead box protein M1 (FOXM1) and polo-like kinase 1 (PLK1), both of which have essential roles in cell cycle regulation, and determine their prognostic value in HCC. To this end, FOXM1 and PLK1 expression levels were assessed in The Cancer Genome Atlas and International Cancer Genome Consortium Japan HCC cohorts, and the associations between their co-expression were determined via Pearson's correlation analysis. Furthermore, the overall survival and disease-free survival in these cohorts for different FOXM1 and PLK1 expression statuses were analyzed. knockdown experiments were also performed using Huh7 cells. The results obtained indicated overexpression of FOXM1 and PLK1 in HCC tumor tissues as well as a positive correlation between FOXM1 and PLK1 expression. The results also suggested that both FOXM1 and PLK1 are required for HCC cell proliferation. In addition, upregulation of FOXM1 and PLK1 was indicated to be associated with poor prognosis of patients with HCC. However, only their coordinated overexpression was identified as an independent prognostic factor for HCC.

摘要

肝细胞癌(HCC)是最常见的恶性肿瘤类型之一,为改善其治疗效果,迫切需要有效的预后生物标志物。细胞周期失调是癌症进展的一个显著特征。本研究的目的是评估在细胞周期调控中起重要作用的叉头框蛋白M1(FOXM1)和 polo样激酶1(PLK1)的表达水平,并确定它们在HCC中的预后价值。为此,在癌症基因组图谱和国际癌症基因组联盟日本HCC队列中评估了FOXM1和PLK1的表达水平,并通过Pearson相关性分析确定了它们共表达之间的关联。此外,分析了这些队列中不同FOXM1和PLK1表达状态下的总生存期和无病生存期。还使用Huh7细胞进行了敲低实验。获得的结果表明,HCC肿瘤组织中FOXM1和PLK1过表达,以及FOXM1和PLK1表达之间呈正相关。结果还表明,HCC细胞增殖需要FOXM1和PLK1。此外,FOXM1和PLK1的上调表明与HCC患者的不良预后相关。然而,只有它们的协同过表达被确定为HCC的独立预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/d3af48646895/ol-23-05-13266-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/c89b2d4c2a50/ol-23-05-13266-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/3103431afb06/ol-23-05-13266-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/31812936862e/ol-23-05-13266-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/559ffc231229/ol-23-05-13266-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/d3af48646895/ol-23-05-13266-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/c89b2d4c2a50/ol-23-05-13266-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/3103431afb06/ol-23-05-13266-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/31812936862e/ol-23-05-13266-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/559ffc231229/ol-23-05-13266-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfa8/8941521/d3af48646895/ol-23-05-13266-g04.jpg

相似文献

1
Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.FOXM1和PLK1的表达可预测肝细胞癌患者的预后。
Oncol Lett. 2022 May;23(5):146. doi: 10.3892/ol.2022.13266. Epub 2022 Mar 15.
2
FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells.叉头框蛋白M1(FOXM1)参与肾癌细胞中由Polo样激酶1(PLK1)调控的细胞周期进程。
Oncol Lett. 2016 Apr;11(4):2685-2691. doi: 10.3892/ol.2016.4228. Epub 2016 Feb 15.
3
PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.PLK1 和 FoxM1 在甲状腺乳头状癌中呈正相关表达,联合抑制它们可产生协同抗肿瘤作用。
Mol Oncol. 2024 Mar;18(3):691-706. doi: 10.1002/1878-0261.13610. Epub 2024 Feb 15.
4
Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.FOXM1 和 Aurora-A 的表达可预测肝细胞癌患者的预后和索拉非尼疗效。
Cancer Biomark. 2020;28(3):341-350. doi: 10.3233/CBM-190507.
5
The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival.Nek7、FoxM1 和 Plk1 在胆囊癌中的表达及其与临床病理特征和生存的关系。
Clin Transl Oncol. 2013 Aug;15(8):626-32. doi: 10.1007/s12094-012-0978-9. Epub 2013 Jan 29.
6
Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression.组蛋白去乙酰化酶抑制剂诱导的CDKN2B和CDKN2D通过抑制叉头框M1导致肝癌细胞氧化应激引起的G2/M期细胞周期阻滞。
J Cancer. 2021 Jun 22;12(17):5086-5098. doi: 10.7150/jca.60027. eCollection 2021.
7
A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.FOXM1 基因表达特征可预测肝细胞癌的预后。
Exp Mol Med. 2018 Jan 5;50(1):e418. doi: 10.1038/emm.2017.159.
8
Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma.叉头框M1转录因子表达增加与人类肝细胞癌的临床病理特征相关,并预示不良预后。
Hepatol Res. 2017 Oct;47(11):1196-1205. doi: 10.1111/hepr.12854. Epub 2017 Feb 3.
9
FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.在胃腺癌患者中,叉头框蛋白M1(FOXM1)和波罗样激酶1(polo-like kinase 1)共同过度表达。
BMC Res Notes. 2015 Nov 14;8:676. doi: 10.1186/s13104-015-1658-y.
10
FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.FOXM1 通过调控 KIF4A 的表达促进肝癌进展。
J Exp Clin Cancer Res. 2019 May 9;38(1):188. doi: 10.1186/s13046-019-1202-3.

引用本文的文献

1
PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities.PLK1在癌症治疗中的作用:免疫调节机制与治疗机会的全面综述
Front Immunol. 2025 Jun 19;16:1602752. doi: 10.3389/fimmu.2025.1602752. eCollection 2025.
2
Research progress on FOXM1 in ovarian cancer diagnosis and therapeutics.FOXM1在卵巢癌诊断与治疗中的研究进展
Front Oncol. 2025 Jun 19;15:1598868. doi: 10.3389/fonc.2025.1598868. eCollection 2025.
3
Establishment and Validation of the Novel Necroptosis-related Genes for Predicting Stemness and Immunity of Hepatocellular Carcinoma Machine-learning Algorithm.

本文引用的文献

1
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.调节性 T 细胞在自身免疫和癌症中的双重生活方式
Front Immunol. 2021 Sep 3;12:731947. doi: 10.3389/fimmu.2021.731947. eCollection 2021.
2
Cell cycle control in cancer.癌症中的细胞周期调控。
Nat Rev Mol Cell Biol. 2022 Jan;23(1):74-88. doi: 10.1038/s41580-021-00404-3. Epub 2021 Sep 10.
3
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
用于预测肝细胞癌干性和免疫性的新型坏死性凋亡相关基因的建立与验证 机器学习算法
Comb Chem High Throughput Screen. 2025;28(1):146-165. doi: 10.2174/0113862073271292231108113547.
4
The conformation of FOXM1 homodimers in vivo is crucial for regulating transcriptional activities.FOXM1 同二聚体在体内的构象对于调节转录活性至关重要。
Nucleic Acids Res. 2024 Dec 11;52(22):13625-13643. doi: 10.1093/nar/gkae988.
5
PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.PLK1 和 FoxM1 在甲状腺乳头状癌中呈正相关表达,联合抑制它们可产生协同抗肿瘤作用。
Mol Oncol. 2024 Mar;18(3):691-706. doi: 10.1002/1878-0261.13610. Epub 2024 Feb 15.
6
PLK1 phosphorylates RhoGDI1 and promotes cancer cell migration and invasion.PLK1使RhoGDI1磷酸化并促进癌细胞迁移和侵袭。
Cancer Cell Int. 2024 Feb 14;24(1):73. doi: 10.1186/s12935-024-03254-z.
7
Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with Variant rs27770A>G.hsa-miR-100-5p表达增加改善了亚洲人群中rs27770A>G变异型肝细胞癌的预后。
Cancers (Basel). 2023 Dec 27;16(1):129. doi: 10.3390/cancers16010129.
8
Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma.肝细胞癌中差异表达基因的综合分析及治疗见解
Cancers (Basel). 2023 Nov 30;15(23):5653. doi: 10.3390/cancers15235653.
9
The expression and clinical significance of PLK1/p-PLK1 protein in NK/T cell Lymphoma.PLK1/p-PLK1 蛋白在 NK/T 细胞淋巴瘤中的表达及临床意义。
Diagn Pathol. 2023 Nov 30;18(1):129. doi: 10.1186/s13000-023-01413-w.
10
SAMD13 serves as a useful prognostic biomarker for hepatocellular carcinoma.SAMD13 可作为肝细胞癌有价值的预后生物标志物。
Eur J Med Res. 2023 Nov 15;28(1):514. doi: 10.1186/s40001-023-01347-5.
信迪利单抗联合贝伐珠单抗生物类似药(IBI305)对比索拉非尼治疗不可切除肝细胞癌(ORIENT-32):一项随机、开放标签的2/3期研究
Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.
4
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.肝癌肿瘤免疫微环境与免疫抑制治疗:综述。
Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801.
5
PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.PLK1/波形蛋白信号通过将 Smad2/3 募集到转移性肺腺癌的 PD-L1 启动子上来促进免疫逃逸。
Cell Death Differ. 2021 Sep;28(9):2745-2764. doi: 10.1038/s41418-021-00781-4. Epub 2021 May 7.
6
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.细胞周期的致癌和抑癌成分在乳腺癌进展及预后中的作用
Pharmaceutics. 2021 Apr 17;13(4):569. doi: 10.3390/pharmaceutics13040569.
7
Advances in immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗进展。
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. doi: 10.1038/s41575-021-00438-0. Epub 2021 Apr 13.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
10
PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.PLK1/NF-κB 前馈回路拮抗 PARP10 的单 ADP-核糖基转移酶活性,促进 HCC 进展。
Oncogene. 2020 Apr;39(15):3145-3162. doi: 10.1038/s41388-020-1205-8. Epub 2020 Feb 14.